Want to see CLLS full AI Analyst Report?
CLLS Stock Chart & Stats
$4.42
-$0.20(-9.46%)
At close: 4:00 PM EST
$4.42
-$0.20(-9.46%)
Day’s Range― - ―
52-Week Range$1.77 - $5.48
Previous CloseN/A
Volume129.50K
Average Volume (3M)39.79K
Market Cap
$191.13M
Enterprise Value$241.61
Total Cash (Recent Filing)$185.66M
Total Debt (Recent Filing)$108.60M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Jul 30, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding72,325,455
10 Day Avg. Volume15,682
30 Day Avg. Volume39,787
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)6.39
Price to Sales (P/S)6.65
P/FCF Ratio-11.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside103.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$60.82M
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyAnalyst highlights that lasme-cel produced a strong complete response rate in heavily pretreated B‑cell acute lymphoblastic leukemia patients, supporting the therapy's potential for regulatory approval and clinical adoption.
Manufacturing CapabilitiesAnalyst views in‑house manufacturing of the allogeneic CAR T candidate as a competitive advantage that could reduce reliance on external partners and improve supply consistency.
Regulatory ProgressAnalyst expects the planned Biologics License Application in 2028 combined with forthcoming Eti‑cel data updates to clarify commercial prospects and reduce regulatory uncertainty.
Bears Say
Commercial FeasibilityAnalyst cautions that high treatment cost and the need for multiple CAR T infusions followed by stem cell transplants could limit payer coverage and patient access, constraining market uptake.
Liquidity And FinancingAnalyst points out the anticipated $28 million cash burn could strain liquidity and necessitate additional financing, raising dilution and execution risks if capital markets are unfavorable.
Trial Enrollment RiskAnalyst warns that slow enrollment in the pivotal Phase 2 trial could delay key readouts and push back regulatory timelines, increasing development uncertainty.
Cellectis SA News
CLLS FAQ
What was Cellectis S.A.’s price range in the past 12 months?
Cellectis S.A. lowest stock price was $1.77 and its highest was $5.48 in the past 12 months.
What is Cellectis S.A.’s market cap?
Cellectis S.A.’s market cap is $191.13M.
When is Cellectis S.A.’s upcoming earnings report date?
Cellectis S.A.’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Cellectis S.A.’s earnings last quarter?
Cellectis S.A. released its earnings results on May 11, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.258 by $0.078.
Is Cellectis S.A. overvalued?
According to Wall Street analysts Cellectis S.A.’s price is currently Undervalued.
Does Cellectis S.A. pay dividends?
Cellectis S.A. does not currently pay dividends.
What is Cellectis S.A.’s EPS estimate?
Cellectis S.A.’s EPS estimate is -0.26.
How many shares outstanding does Cellectis S.A. have?
Cellectis S.A. has 72,325,455 shares outstanding.
What happened to Cellectis S.A.’s price movement after its last earnings report?
Cellectis S.A. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.258. Following the earnings report the stock price went down -0.503%.
Which hedge fund is a major shareholder of Cellectis S.A.?
Currently, no hedge funds are holding shares in CLLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cellectis SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (103.62% Upside)
$9.00 (103.62% Upside)
Blogger Sentiment
Bullish
CLLS Sentiment 70%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.38%
12-Months-Change
Fundamentals
Return on Equity
-80.61%
Trailing 12-Months
Asset Growth
-20.57%
Trailing 12-Months
Company Description
Cellectis S.A.
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
CLLS Stock 12 Month Forecast
Average Price Target
$9.00
▲(103.62% Upside)
Technical Analysis
Cartesian Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Zura Bio
―
Ownership Overview
―
Insiders
0.94% Mutual Funds
9.28% Other Institutional Investors
89.46% Public Companies and
Individual Investors